Cobaltous Chloride
Brand names: Ceretec · Active ingredient: Cobaltous Chloride
In short: Ceretec, when reconstituted with technetium Tc 99m exametazime (without cobalt stabilizer solution), is indicated in adults and pediatric patients age 2 to 17 for leukocyte labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease. Ceretec, whe
What is Cobaltous Chloride used for?
Ceretec, when reconstituted with technetium Tc 99m exametazime (without cobalt stabilizer solution), is indicated in adults and pediatric patients age 2 to 17 for leukocyte labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease.
Ceretec, when reconstituted with technetium Tc 99m exametazime (with or without cobalt stabilizer solution), is indicated in adults and pediatric patients age 2 to 17 for cerebral scintigraphy as an adjunct in the detection of altered regional cerebral perfusion in stroke.
Cobaltous Chloride dosage
The Ceretec kit includes a cobalt stabilizer solution, which is optional for cerebral scintigraphy. DO NOT USE COBALT STABILIZER SOLUTION FOR LEUKOCYTE LABELED Scintigraphy
.
Technetium Tc 99m exametazime injection is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure . Use waterproof gloves and effective shielding, including syringe shields, when preparing and administering technetium Tc 99m exametazime injection.
Leukocyte Labeled Scintigraphy
Dosing
Adults: The recommended dose is 185 MBq to 370 MBq (5 mCi to 10 mCi) of Tc 99m exametazime labeled leukocytes by intravenous injection. Administer using a 19G needle as soon as possible, preferably within 20 minutes but no later than 1 hour, after preparing the Tc 99m labeled leukocyte suspension.
Pediatric patients age 2 to 17: The recommended dose is 7.4 MBq/kg (0.2 mCi/kg); with a minimum of 74 MBq (2 mCi). Do not exceed the maximum administered activity for an adult.
Imaging Procedures
Instruct patients to empty their bladder prior to imaging.
Dynamic imaging may be performed for the first 60 minutes after injection to assess lung clearance and to visualize cell migration.
Perform static imaging at 0.5-1.5 hours, 2-4 hours and if necessary, at 18-24 hours after administration to detect focal accumulation of activity.
Cerebral Scintigraphy
Dosing
Adults: The recommended dose is 555 MBq to 1110 MBq (15 mCi to 30 mCi) by intravenous injection.
Pediatric patients age 2 to 17: The recommended dose is 14.0 MBq/kg (0.4 mCi/kg); with a minimum of 110 MBq (3.0 mCi). Do not exceed the maximum administered activity for an adult.
Imaging Procedures
Images may be acquired by planar or SPECT imaging techniques.
Perform imaging 30-90 min. after administration and complete imaging within 4 hrs after administration.
General Preparation and Administration Instructions
Use aseptic procedures throughout preparation and handling.
Visually inspect the reconstituted technetium Tc 99m exametazime injection prior to use and do not use if there is evidence of particulate matter or discoloration.
Measure patient dose with a dose calibrator immediately prior to administration.
Instruct patients to maintain adequate hydration, after administration of technetium Tc 99m exametazime labeled white blood cells or Tc 99m exametazime injection and void frequently to minimize radiation dose to the kidneys and bladder .
Reconstitution Instructions
Elute the technetium Tc 99m generator according to the manufacturer's instructions.
Only use eluate from a technetium Tc 99m generator which has been eluted within the previous 24 hours.
For the highest radiochemical purity reconstitute with freshly eluted technetium 99m generator eluate. …
How to take Cobaltous Chloride — instructions & advice from the label
Administration Instructions
Instruct patients to remain hydrated and void frequently following administration to decrease radiation exposure .
Pregnancy
Advise pregnant women of the risk of fetal exposure to radiation doses if they undergo a radionuclide imaging study .
Lactation
Advise a lactating woman to pump and discard breast milk for 12-24 hours (based on injection dose) after administration to minimize radiation exposure to the breastfed infant .
Warnings & precautions
Do not take this medicine if: None
Hypersensitivity reactions have been reported following the administration of Tc 99m exametazime injection and Tc 99m exametazime labeled leukocytes including serious signs and symptoms of anaphylaxis following administration . Always have cardiopulmonary resuscitation equipment and personnel available and monitor all patients for hypersensitivity reactions.
The interpretation of images for leukocyte labeled imaging can be affected by the presence of other pathophysiological processes such as: tumor, infarction, trauma, and inflammatory conditions.
Technetium Tc 99m contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Encourage patients to drink fluids and instruct patients to void when the examination is completed and as often thereafter as frequently as possible after administration . Radiation risks associated with the use of Tc 99m exametazime injection and Tc 99m exametazime labeled leukocytes are greater in pediatric patients than in adults due to greater radiosensitivity and longer life expectancy.
Cobaltous Chloride side effects
The following serious adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions .
The following adverse reactions associated with the use of Ceretec were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular disorders: Reversible increase in blood pressure, flushing
Gastrointestinal disorders: Nausea, vomiting
General disorders and administration site conditions: Malaise, fatigue, fever
Immune system disorders: Hypersensitivity reactions: anaphylactic reactions including shock, facial edema, rash, pruritus or erythema
Nervous system disorders: Headache, dizziness, paresthesia
About this medicine
Ceretec (kit for the preparation of technetium Tc 99m exametazime injection) prepares a radioactive diagnostic agent for intravenous use.
Each unit consists of the following:
One 10 mL vial of exametazime containing a sterile, non-pyrogenic, lyophilized mixture of 0.5 mg exametazime, 7.6 mcg stannous chloride dihydrate (minimum stannous tin 0.6 mcg; maximum total stannous and stannic tin 4 mcg per vial) and 4.5 mg sodium chloride, sealed under nitrogen atmosphere with a rubber closure. The product contains no antimicrobial preservative.
One vial of cobalt stabilizer containing a sterile, non-pyrogenic solution of 200 mcg cobaltous chloride 6-hydrate in 2 mL of Water for Injection.
The chemical name for Exametazime is [(RR,SS)-4.8-diaza-3,6,6,9-tetramethylundecane-2, 10-dione bisoxime]. The molecular formula of exametazime is C13H28N4O2, with the following structural formula:
Prior to publication of the USAN, exametazime was known as hexamethylpropylene amine oxime (HM-PAO). The name HM-PAO appears in many publications. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d9c291e0-cd0d-43d2-87b4-defefd531942. Read the full official label on DailyMed.